ClinicalTrials.gg
CompletedNCT06029855Updated Mar 28, 2025

Kabat Rehabilitation Versus Mime Therapy on Facial Disability and Synkinesis in Patients of Bell's Palsy

An interventional study of Kabat Therapy and Mime Therapy in Bell Palsy, sponsored by University of Lahore. Completed at 1 site in Pakistan. Open to participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by University of Lahore · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2023, registered Sep 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
25 Years to 50 Years
Sex
All
01

Study summary

Bell's palsy, also called idiopathic facial paralysis, is a common cause of unilateral facial paralysis. It is one of the most common neurological disorders of the cranial nerves.

Read the detailed description

Bell's palsy is an alarming condition of rapid onset, which paralyzes half of the facial muscles. Kabat rehabilitation is a manual resistance technique that promotes a basic pattern of movement through facilitation, inhibition, and resistance of a group of muscles. It increases the functioning and power of facial muscles while Mime therapy results in immediate improvement of function and integrity of facial muscles. It also mitigates synkinesis in Bell's palsy. Both techniques are easy to apply. They are clinically important techniques that are easily understood by patients.

02

Conditions studied

  • Bell Palsy

Browse trials for

Keywords

  • Bell Palsy
  • Kabat Rehabilitation
  • Mime Therapy
03

In context

Bell Palsy

85 studies on the registry are indexed under Bell Palsy; 30 are open to participants now.

This study's enrollment of 85 is above the median of 42 across 70 interventional studies indexed under Bell Palsy.

Browse Bell Palsy studies →

Lead sponsor

University of Lahore is the lead sponsor of 232 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age group 25-50 years.
  2. Both male and female.
  3. Unilateral bell's paralysis.
  4. Not congenital in origin.
  5. Sub-acute and chronic cases.

Exclusion criteria

Exclusion Criteria:

  1. Other neurological deficits include epilepsy and Alzheimer's disease.
  2. Traumatic onset.
  3. Surgical reconstruction (nerve or muscle reconstruction).
  4. Mental and psychological disorders i.e., schizophrenia, bipolar disorders.
  5. Skin diseases (eczema, urticarial) as electrical stimulation may affect the results.
  6. Any for massage like sunburn, bruising, or cuts.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Active comparator
    Kabat Therapy

    Kabat exercises primarily assist functional response in defective muscles through the general structure of muscles experiencing resistance. After 6th week, resting and voluntary symmetries were recorded.

    Other: Kabat Therapy

  • Experimental
    Mime Therapy

    Mime therapy utilizes emotional input to access better movement patterns. It is beneficial as it improves circulation and maintains muscle properties.

    Other: Mime Therapy

Interventions

  • OtherKabat Therapy

    The participants of group A will receive Kabat Rehabilitation with routine physical therapy. The protocol will be given to the participants for three sessions/week for six weeks. Each session will be of 30 minutes.

  • OtherMime Therapy

    The participants of group B will receive Mime Therapy in addition to routine physical therapy. The protocol will be given to the participants once a week for six weeks, while physical therapy will be given on alternate days. Each session will be of 30 minutes.

06

What researchers measure

Primary outcomes

  1. Change in Synkinesis

    Synkinesis will be accessed through the "House-Brackmann Scale". It is classified as a universal scale. This scale analyses the symmetry, synkinesis, stiffness, and global mobility of the face. It is divided into six categories (normal, mild dysfunction, moderate dysfunction, moderately severe dysfunction, severe dysfunction, and total paralysis) and is a 0-6-point scale with 6 representing total paralysis.

    Time frame: It will be assessed at baseline, at the third week and at six week.

  2. Level of Facial Disability

    The level of Facial disability will be measured through the "Facial Disability Index Scale". This scale has ten items that evaluate the patient's physical and social aspects (mastication, deglutition, communication, labial mobility, emotional alterations, and social integration). It uses a hundred-point scale with a higher score indicating less impairment. 24 Minimum score for physical functioning: 0, Maximum score for physical functioning: 25, Minimum score for social and well-being: 5, Maximum score for social and well-being.

    Time frame: Change in functional status will be measured at the baseline, at 3rd week and at 6th week.

07

Study locations

1 site
  • The University of Lahore
    Lahore, Punjab 5400, Pakistan
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: Immediately after publication

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029855
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
May 1, 2023
Primary completion
Sep 30, 2023
Completion
Oct 15, 2023
Last update
Mar 28, 2025

Study contacts

Ashfaq Dr Ahmed, PhD
study chair · The University of Lahore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion